Humanized anti-CXCR5 antibodies, derivatives thereof and their use
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-039/395
C07K-016/28
G06F-019/12
A61K-039/00
출원번호
US-0794244
(2013-03-11)
등록번호
US-9243067
(2016-01-26)
발명자
/ 주소
Lee, Renata
Mikol, Vincent
Allen, Elizabeth
Ruetsch, Norman
Cameron, Beatrice
Oligino, Thomas
Baurin, Nicholas
출원인 / 주소
SANOFI
대리인 / 주소
Szczepanik, Ann Marie
인용정보
피인용 횟수 :
0인용 특허 :
71
초록
The present invention relates to humanized antibodies that specifically bind to CXCR5 and can, for example, inhibit CXCR5 function. The invention also includes uses of the antibodies to treat or prevent CXCR5 related diseases or disorders.
대표청구항▼
1. An isolated monoclonal antibody or fragment thereof that competitively inhibits the binding of an anti-CXCR5 antibody or fragment thereof to the extracellular domain of human CXCR5, wherein the anti-CXCR5 antibody or fragment thereof comprises: (a) a light chain variable domain comprising the ami
1. An isolated monoclonal antibody or fragment thereof that competitively inhibits the binding of an anti-CXCR5 antibody or fragment thereof to the extracellular domain of human CXCR5, wherein the anti-CXCR5 antibody or fragment thereof comprises: (a) a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 11, and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 12;(b) the amino acid sequences of RSSKSLLHSSGKTYLY (SEQ ID NO: 58), RMSNLAS (SEQ ID NO: 59), MQHLEYPYT (SEQ ID NO: 60), GFSLIDYGVN (SEQ ID NO: 61), VIWGDGTTY (SEQ ID NO: 62), and IVY (SEQ ID NO: 63):(c) a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID NO: 15, and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 16;(d) the amino acid sequences of RSSKSLLHSSGKTYLY (SEQ ID NO: 58), RLSNLAS (SEQ ID NO: 64), MQHLEYPYT (SEQ ID NO: 60), GFSLIDYGVN (SEQ ID NO: 61), VIWGDGTTY (SEQ ID NO: 62), and IVY (SEQ ID NO: 63);(e) the amino acid sequences of RSSKSLLHSSGKTYLY (SEQ ID NO: 58), RLSSNLAS (SEQ ID NO: 65), MQHLEYPYT (SEQ ID NO: 60), GFSLIDYGVN (SEQ ID NO: 61), VIWGDGTTY (SEQ ID NO: 62), and IVY (SEQ ID NO: 63);(f) a variable light chain (VL) comprising the amino acid sequence of SEQ ID NO: 17, SEQ ID NO: 19, or SEQ ID NO: 21, and a variable heavy chain (VH) comprising the amino acid sequence of SEQ ID NO: 23;(g) a variable light chain comprising the amino acid sequence of SEQ ID NO: 30, SEQ ID NO: 31, or SEQ ID NO: 32, and a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 33 or SEQ ID NO: 34;(h) the amino acid sequences of RSSKSLLHSSGKTYLY (SEQ ID NO: 58), RMSNLA (SEQ ID NO: 66), MQHLEYPYT (SEQ ID NO: 60), GFSLIDYGVN (SEQ ID NO: 61), VIWGDGTTY (SEQ ID NO: 62), and IVY (SEQ ID NO: 63);(i) the amino acid sequences of RSSKSLLHSSGKTYLY (SEQ ID NO: 58), RLSNLA (SEQ ID NO: 68), MQHLEYPYT (SEQ ID NO: 60), GFSLIDYGVN (SEQ ID NO: 61), VIWGDGTTY (SEQ ID NO: 62), and IVY (SEQ ID NO: 63);(j) the amino acid sequences of RSSKSLLHSSGKTYLY (SEQ ID NO: 58), RLSSLA (SEQ ID NO: 68), MQHLEYPYT (SEQ ID NO: 60), GFSLIDYGVN (SEQ ID NO: 61), VIWGDGTTY (SEQ ID NO: 62), and IVY (SEQ ID NO: 63);(k) a variable light chain comprising the amino acid sequence of SEQ ID NO: 35, and a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 37;(l) a variable light chain comprising the amino acid sequence of SEQ ID NO: 39, SEQ ID NO: 41, or SEQ ID NO: 43, and a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 45 or SEQ ID NO: 47;(m) a variable light chain comprising the amino acid sequence of SEQ ID NO: 55, and a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 56 or SEQ ID NO: 57; or(n) the amino acid sequences of RSSKSLLHSSGKTYLYW (SEQ ID NO: 69), RMSNLA (SEQ ID NO: 66), MQHLEYPYT (SEQ ID NO: 60), GFSLIDYGVN (SEQ ID NO: 61), VIWGDGTTY (SEQ ID NO: 62), and IVY (SEQ ID NO: 63). 2. An isolated monoclonal antibody or fragment thereof that competitively inhibits the binding of an anti-CXCR5 antibody or fragment thereof to the extracellular domain of human CXCR5, wherein the anti-CXCR5 antibody or fragment thereof comprises a variable light chain comprising the amino acid sequence of SEQ ID NO: 32, and a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 33. 3. An isolated monoclonal antibody or fragment thereof that competitively inhibits the binding of an anti-CXCR5 antibody or fragment thereof to the extracellular domain of human CXCR5, wherein the anti-CXCR5 antibody or fragment thereof comprises the amino acid sequences of RSSKSLLHSSGKTYLY (SEQ ID NO: 58), RLSSLA (SEQ ID NO: 68), MQHLEYPYT (SEQ ID NO: 60), GFSLIDYGVN (SEQ ID NO: 61), VIWGDGTTY (SEQ ID NO: 62), and IVY (SEQ ID NO: 63). 4. The antibody or fragment thereof of any one of claims 1, 2, or 3, wherein the antibody or fragment thereof further comprises one or more constant region domains. 5. The antibody or fragment thereof of any one of claims 1, 2, or 3, wherein the antibody or fragment thereof further comprises a CH1, CH2, CH3, or combinations thereof. 6. The antibody or fragment thereof of claim 4, wherein the one or more constant region domains are from an IgG antibody. 7. The antibody or fragment thereof of claim 6, wherein the IgG antibody is an IgG4 antibody. 8. The antibody or fragment thereof of any one of claims 1, 2, or 3, wherein the antibody or fragment thereof is a single chain Fv antibody. 9. A pharmaceutical composition comprising a therapeutically effective amount of the antibody or fragment thereof of any one of claims 1, 2, or 3 and a pharmaceutically acceptable carrier.
Lynch, Carmel M.; Burstein, Haim; Stepan, Anthony M.; Lockert, Dara H., Amplifiable adeno-associated virus(AAV) packaging cassettes for the production of recombinant AAV vectors.
Chari Ravi V. J. (Newton MA) Goldmakher Viktor S. (Newton MA) Blattler Walter A. (Brookline MA), Cell binding agent conjugates of analogues and derivatives of CC-1065.
Parenteau Nancy Louise ; Johnson Eric William ; Meunier Susan Frances ; Maresh John Gregory, Chemically defined cell culture media and system and methods for use, particularly for culturing epithelial cells.
Ladner Robert C. (Ijamsville MD) Guterman Sonia K. (Belmont MA) Roberts Bruce L. (Milford MA) Markland William (Milford MA) Ley Arthur C. (Newton MA) Kent Rachel B. (Boxborough MA), Directed evolution of novel binding proteins.
Shenk Thomas E. (Princeton NJ) Samulski Richard J. (Pittsburgh PA) Chang Long-Sheng (Linden NJ), Helper-free stocks of recombinant adeno-associated virus vectors.
Boguslaski Robert C. (Elkhart IN) Carrico Robert J. (Bremen IN) Christner James E. (Ann Arbor MI), Heterogenous specific binding assay employing a cycling reactant as label.
Kucherlapati Raju (Darien CT) Koller Beverly H. (Carrboro NC) Smithies Oliver (Chapel Hill NC), Homologous recombination for universal donor cells and chimeric mammalian hosts.
Cunningham Brian C. (Piedmont CA) Lowman Henry (Hercules CA) Wells James A. (Burlingame CA), Human growth hormone variants having greater affinity for human growth hormone receptor at site 1.
Morgan Jeffrey R. (Brighton MA) Mulligan Richard C. (Cambridge MA), In vivo introduction and expression of foreign genetic material in epithelial cells.
Mather Jennie P. (Millbrae CA) Tsao Mary C. (Burlingame CA), Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins.
Freedman Bernard (Peoria IL) Powell Richard G. (Peoria IL) Smith ; Jr. Cecil R. (Dunlap IL), Method of controlling the European corn borer with trewiasine.
Morrison Sherie L. ; Herzenberg Leonard A. ; Oi Vernon T., Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric.
Robinson Randy R. (Los Angeles CA) Liu Alvin Y. (Oceanside CA) Horwitz Arnold H. (Los Angeles CA) Better Marc (Los Angeles CA) Wall Randolph (Sherman Oaks CA) Lei Shau-Ping (Los Angeles CA) Wilcox Ga, Modular assembly of antibody genes, antibodies prepared thereby and use.
Robinson Randy R. (Los Angeles CA) Liu Alvin Y. (Oceanside CA) Horwitz Arnold H. (Los Angeles CA) Better Marc (Los Angeles CA) Wall Randolph (Sherman Oaks CA) Lei Shau-Ping (Los Angeles CA) Wilcox Ga, Modular assembly of antibody genes, antibodies prepared thereby and use.
Robinson Randy R. ; Liu Alvin Y. ; Horwitz Arnold H. ; Better Marc ; Wall Randolph ; Lei Shau-Ping ; Wilcox Gary L., Modular assembly of antibody genes, antibodies prepared thereby and use.
Boss Michael A. (Slough GBX) Kenten John H. (High Wycombe GBX) Emtage John S. (High Wycombe GBX) Wood Clive R. (Near Fordingbridge GBX), Multichain polypeptides or proteins and processes for their production.
Davis Frank F. (19 Farmingdale Rd. East Brunswick NJ 08816) Van Es Theodorus (313 Overbrook Rd. Piscataway NJ 08854) Palczuk Nicholas C. (45 W. Franklin St. Bound Brook NJ 08805), Non-immunogenic polypeptides.
Griffiths Andrew David,GBX ; Hoogenboom Hendricus Renerus Jacobus Mattheus,GBX ; Marks James David ; McCafferty John,GBX ; Winter Gregory Paul,GBX ; Grigg Geoffrey Walter,AUX, Production of anti-self antibodies from antibody segment repertoires and displayed on phage.
Hoogenboom Hendricus R. J. M. (Cambridge GBX) Baier Michael (Frankfurt DEX) Jespers Laurent S. A. T. (Tervuren BEX) Winter Gregory P. (Cambridge GBX), Production of chimeric antibodies - a combinatorial approach.
Pedersen Jan T. (Bath GBX) Searle Stephen M. J. (Bath GBX) Rees Anthony R. (Bath GBX) Roguska Michael A. (Ashland MA) Guild Braydon C. (Concord MA), Resurfacing of rodent antibodies.
Lonberg Nils (San Francisco CA) Kay Robert M. (San Francisco CA), Transgenic non-human animals capable of producing heterologous antibodies of various isotypes.
Lonberg Nils (San Francisco CA) Kay Robert M. (San Francisco CA), Transgenic non-human animals capable of producing heterologous antibodies of various isotypes.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.